Evaluation of feline monocyte-derived dendritic cells loaded with internally inactivated virus as a vaccine against feline immunodeficiency virus

Clinical and Vaccine Immunology

Volumn 15, Issue 3, 2008, Pages 452-459

  Freer, Giulia ^a   Matteucci, Donatella ^a   Mazzetti, Paola ^a   Tarabella, Francesca ^a   Catalucci, Valentina ^a   Ricci, Enrica ^a   Merico, Antonio ^a   Bozzacco, Leonia ^a   Pistello, Mauro ^a   Bendinelli, Mauro ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALDITHRIOL 2; CD4 ANTIGEN; CD8 ANTIGEN; CHEMICAL AGENT; DENDRITIC CELL VACCINE; GLYCOPROTEIN GP 120; HLA B7 ANTIGEN; HLA B7.1 ANTIGEN; IMIQUIMOD; IMMUNOLOGICAL ADJUVANT; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PROTEIN P25; INACTIVATED VACCINE; VIRUS ANTIBODY; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; CAT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG EFFICACY; EVALUATION; FELINE IMMUNODEFICIENCY VIRUS; FEMALE; HELPER CELL; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOTHERAPY; MONOCYTE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROVIRUS; QUANTITATIVE ANALYSIS; TH1 CELL; TH2 CELL; VACCINATION; VIRUS INACTIVATION; VIRUS ISOLATION; VIRUS LOAD; ANIMAL; BLOOD; CAT DISEASE; CYTOLOGY; GERMFREE ANIMAL; IMMUNOLOGY; ISOLATION AND PURIFICATION; LYMPHOCYTE ACTIVATION; MONONUCLEAR CELL; PATHOGENICITY; PATHOPHYSIOLOGY; VIROLOGY;

ANIMALS; ANTIBODIES, VIRAL; CATS; DENDRITIC CELLS; FELINE ACQUIRED IMMUNODEFICIENCY SYNDROME; FEMALE; IMMUNODEFICIENCY VIRUS, FELINE; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; MONOCYTES; SPECIFIC PATHOGEN-FREE ORGANISMS; VACCINES, INACTIVATED; VIRAL VACCINES;

EID: 42049087462     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00421-07     Document Type: Article

References (27)

1. Dunham, S. 2006. Lessons from the cat: development of vaccines against lentiviruses. Vet. Immunol. Immunopathol. 112:67-77.
2. Figdor, C. G., I. J. de Vries, W. J. Lesterhuis, and C. J. Melief. 2004. Dendritic cell immunotherapy: mapping the way. Nat. Med. 10:475-480.
3. Freer, G., D. Matteucci, P. Mazzetti, L. Bozzacco, and M. Bendinelli. 2005. Generation of feline dendritic cells derived from peripheral blood monocytes for in vivo use. Clin. Diagn. Lab. Immunol. 12:1202-1208.
4. Freer, G., D. Matteucci, P. Mazzetti, F. Tarabella, V. Catalucci, and M. Bendinelli. 2007. Effects of feline immunodeficiency virus on feline monocyte-derived dendritic cells infected by spinoculation. J. Gen. Virol. 88:2574-2582.
5. Giannecchini, S., P. Isola, O. Sichi, D. Matteucci, M. Pistello, L. Zaccaro, D. Del Mauro, and M. Bendinelli. 2002. AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: failure to protect and possible enhancement of challenge infection by four cell-based vaccines prepared with autologous lymphoblasts. J. Virol. 76:6882-6892.
6. Heeney, J. L., and S. A. Plotkin. 2006. Immunological correlates of protection from HIV infection and disease. Nat. Immunol. 7:1281-1283.
7. Hosie, M. J., R. Osborne, J. K. Yamamoto, J. C. Neil, and O. Jarrett. 1995. Protection against homologous but not heterologous challenge induced by inactivated feline immunodeficiency virus vaccines. J. Virol. 69:1253-1255.
8. Hosie, M. J., and J. A. Beatty. 2007. Vaccine protection against feline immunodeficiency virus: setting the challenge. Aust. Vet. J. 85:5-12.
9. Klase, Z., M. J. Donio, A. Blauvelt, P. A. Marx, K. T. Jeang, and S. M. Smith. 2006. A peptide-loaded dendritic cell based cytotoxic T-lymphocyte (CTL) vaccination strategy using peptides that span SIV Tat, Rev, and Env overlapping reading frames. Retrovirology 3:1-13.
10. Li, W., D. K. Krishnadas, J. Li, D. L. Tyrrell, and B. Agrawal. 2006. Induction of primary human T cell responses against hepatitis C virus-derived antigens NS3 or core by autologous dendritic cells expressing hepatitis C virus antigens: potential for vaccine and immunotherapy. J. Immunol. 176:6065-6075.
11. Lu, W., X. Wu, Y. Lu, W. Guo, and J. M. Andrieu. 2003. Therapeutic dendritic-cell vaccine for simian AIDS. Nat. Med. 9:27-32.
12. Lu, W., L. C. Arraes, W. T. Ferreira, and J. M. Andrieu. 2004. Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat. Med. 10:1359-1365.
13. Matteucci, D., P. Mazzetti, F. Baldinotti, L. Zaccaro, and M. Bendinelli. 1995. The feline lymphoid cell line MBM and its use for feline immunodeficiency virus isolation and quantitation. Vet. Immunol. Immunopathol. 46:71-82.
14. Matteucci, D., M. Pistello, P. Mazzetti, S. Giannecchini, D. Del Mauro, L. Zaccaro, P. Bandecchi, F. Tozzini, and M. Bendinelli. 1996. Vaccination protects against in vivo-grown feline immunodeficiency virus even in the absence of detectable neutralizing antibodies. J. Virol. 70:617-622.
15. Matteucci, D., M. Pistello, P. Mazzetti, S. Giannecchini, D. Del Mauro, I. Lonetti, L. Zaccaro, C. Pollera, S. Specter, and M. Bendinelli. 1997. Studies of AIDS vaccination using an ex vivo feline immunodeficiency virus model: protection conferred by a fixed-cell vaccine against cell-free and cell-associated challenge differs in duration and is not easily boosted. J. Virol. 71:8368-8376.
16. Matteucci, D., A. Poli, P. Mazzetti, S. Sozzi, F. Bonci, P. Isola, L. Zaccaro, S. Giannecchini, M. Calandrella, M. Pistello, S. Specter, and M. Bendinelli. 2000. Immunogenicity of an anti-clade B feline immunodeficiency fixed-cell virus vaccine in field cats. J. Virol. 74:10911-10919.
17. Nair, S., C. McLaughlin, A. Weizer, Z. Su, D. Boczkowski, J. Dannull, J. Vieweg, and E. Gilboa. 2003. Injection of immature dendritic cells into adjuvant-treated skin obviates the need for ex vivo maturation. J. Immunol. 1:6275-6282.
18. Pistello, M., M. Moscardini, P. Mazzetti, S. Macchi, F. Bonci, P. Isola, G. Freer, D. Matteucci, S. Specter, and M. Bendinelli. 2002. Development of feline immunodeficiency virus ORF-A (tat) mutants: in vitro and in vivo characterization. Virology 298:84-95.
19. Pu, J., J. Coleman, E. Coisman, T. Sato, M. Tanabe, J. Arai, and J. K. Yamamoto. 2005. Dual-subtype FIV vaccine (Fel-O-Vax FIV) protection against a heterologous subtype B FIV isolate. J. Feline Med. Surg. 7:65-70.
20. Sallusto, F., and A. Lanzavecchia. 2002. The instructive role of dendritic cells on T-cell responses. Arthritis Res. 4:127-132.
21. Schon, E., A. M. Harandi, I. Nordstrom, J. Holmgren, and K. Eriksson. 2001. Dendritic cell vaccination protects mice against lethality caused by genital herpes simplex virus type 2 infection. J. Reprod. Immunol. 50:87-104.
22. Sparger, E. 2006. FIV as a model for HIV: an overview, p. 149-199. In H. Friedman, S. Specter, and M. Bendinelli (ed.), Infectious agents and pathogenesis: in vivo models of HIV disease and control. Springer, New York, NY.
23. Steinman, R. M., and J. Banchereau. 2007. Taking dendritic cells into medicine. Nature 449:419-426.
24. + T cell apoptosis. J. Infect. Dis. 185:1077-1093.
25. Tüttenberg, A., E. Schmitt, J. Knop, and H. Jonuleit. 2007. Dendritic cellbased immunotherapy of malignant melanoma: success and limitations. J. Dtsch. Dermatol. Ges. 5:190-196.
26. Villadangos, J. A., W. R. Heath, and F. R. Carbone. 2007. Outside looking in: the inner workings of the crosspresentation pathway within dendritic cells. Trends Immunol. 28:45-47.
27. Yamamoto, J. K., T. Okuda, C. D. Ackley, H. Louie, E. Pembroke, H. Zochlinski, R. J. Munn, and M. B. Gardner. 1991. Experimental vaccine protection against feline immunodeficiency virus. AIDS Res. Hum. Retrovir. 7:911-922.